Joo H et al., 2021-03-08: A CDC-authored claims analysis showing US outpatient drug payments for three soil-transmitted helminth infections rose 20.6-137.0 times between 2010 and 2017, driven by antiparasitic price increases, with prescribing shifting away from standard-of-care drugs. It states that mebendazole left the US market in 2011 and returned in 2016 at roughly 80 times the earlier price.
Because the manufacturer, Teva Pharmaceuticals, discontinued producing mebendazole for (non-safety-related) business reasons, mebendazole was withdrawn from the U.S. market in 2011 until 2016, when it was reintroduced at around 80 times increased price.
Introduction
Joo H et al., 2021-03-08: A CDC-authored claims analysis showing US outpatient drug payments for three soil-transmitted helminth infections rose 20.6-137.0 times between 2010 and 2017, driven by antiparasitic price increases, with prescribing shifting away from standard-of-care drugs. It states that mebendazole left the US market in 2011 and returned in 2016 at roughly 80 times the earlier price. Study type: retrospective observational analysis of commercial and Medicaid claims (IBM MarketScan / Truven Treatment Pathways), 2010-2017. Country: United States. N: outpatient visits for ascariasis, hookworm and trichuriasis among continuously enrolled members (visit counts per table; not a fixed cohort). Dose/route/schedule: not applicable (prescription-level analysis). Funder: authors are CDC Division of Global Migration and Quarantine staff plus academic co-authors; funding statement read in full text. Conflicts: as declared in the paper's disclosure section. Product/manufacturer: Teva Pharmaceuticals (generic mebendazole) is named as the withdrawing manufacturer. Comparator: time trend 2010 vs 2017, and standard-of-care vs alternative/non-SOC drug use. The '80 times' figure is attributed by the authors to other sources (their refs 9, 10), not measured in their claims data.
